Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | NT5E | P21589 | 3/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29148038 | 1.00 | LMNA (0.48) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL30303123 | 1.00 | LMNA (0.48) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL18041225 | 1.00 | LMNA (0.48) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL15841130 | 0.94 | NT5E (0.42) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL24829628 | 0.93 | NT5E (0.44) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL19777955 | 0.93 | NT5E (0.44) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL17453217 | 0.93 | NT5E (0.44) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL14652919 | 0.93 | NT5E (0.44) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL930787 | 0.93 | NT5E (0.44) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL930786 | 0.93 | NT5E (0.44) | LMNATP53ALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667053-A2 | BETA-D-2'-DEOXY-2'ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | ATEA Pharmaceuticals, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-3265102-B1 | BETA-D-2'-DEOXY-2'ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | ATEA PHARMACEUTICALS INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250243235-A1 | Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6- SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| US-12084473-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240226131-A1 | 2'-CHLORO-2'-FLUORO-N2-AMINO-N6-METHYLAMINO PURINE NUCLEOTIDES FOR FLAVIVIRUS TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2024-07-11 | — | — | US | disclosed |
| US-11975016-B2 | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment | Atea Pharmaceuticals, Inc. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20240002426-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2024-01-04 | — | — | US | disclosed |
| US-20230017958-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2023-01-19 | — | — | US | disclosed |
| EP-4088725-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF A VIRUS FROM THE PICORNAVIRIDAE FAMILY | ATEA Pharmaceuticals, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| US-20220267366-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2022-08-25 | — | — | US | disclosed |
| US-20180030081-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. | 2018-02-01 | — | — | US | disclosed |
| US-20180030081-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. | 2018-02-01 | — | — | US | disclosed |
| US-20180030082-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. | 2018-02-01 | — | — | US | disclosed |
| EP-3265102-A1 | BETA-D-2'-DEOXY-2'ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | ATEA Pharmaceuticals, Inc. (US) | 2018-01-10 | — | — | EP | disclosed |
| US-9828410-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828410-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2017-11-28 | — | — | US | disclosed |
| WO-2016144918-A1 | β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2016-09-15 | — | — | WO | disclosed |
| US-20160257706-A1 | Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160257706-A1 | Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160024136-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226131-A1 | 2'-CHLORO-2'-FLUORO-N2-AMINO-N6-METHYLAMINO PURINE NUCLEOTIDES FOR FLAVIVIRUS TREATMENT | NSUN2, PNP, METTL3 | LMNA 2440/4885TP53 2624/4885ALDH1A1 2538/4885 |
| US-20220267366-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | LMNA 1290/4885TP53 1000/4885ALDH1A1 1397/4885 |
| US-12084473-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | NSUN2, PNP, NUDT1 | LMNA 1327/4885TP53 1099/4885ALDH1A1 1295/4885 |
| US-11975016-B2 | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment | NSUN2, ADAR, NSUN3 | LMNA 2347/4885TP53 685/4885ALDH1A1 1890/4885 |
| US-20180030081-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | LMNA 1290/4885TP53 1000/4885ALDH1A1 1397/4885 |
| US-20250243235-A1 | Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6- SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | LMNA 1290/4885TP53 1000/4885ALDH1A1 1397/4885 |
| US-20180030082-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | LMNA 1379/4885TP53 1055/4885ALDH1A1 1322/4885 |
| US-20160024136-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | LMNA 2079/4885TP53 1615/4885ALDH1A1 1431/4885 |
| US-20240002426-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | LMNA 1290/4885TP53 1000/4885ALDH1A1 1397/4885 |
| US-20230017958-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | NSUN2, ADAR, NSUN3 | LMNA 2421/4885TP53 635/4885ALDH1A1 1861/4885 |
| US-20160257706-A1 | Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | LMNA 1290/4885TP53 1000/4885ALDH1A1 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.